Advertisement

Renal Cancer — Clinical Studies in the U.S.A.

  • J. D. Schmidt
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)

Abstract

The five year survival for untreated renal cell cancer is approximately 2%. This increases to 30 – 47% following simple nephrectomy whereas the overall five year survival following radical (perifascial) nephrectomy is 57 – 80%. Ten year survivals for renal cell cancer overall are 17 – 27% for simple nephrectomy and 40 – 66% following radical nephrectomy (1–5).

Keywords

Renal Cell Carcinoma Renal Cell Renal Cell Cancer Radical Nephrectomy Medroxyprogesterone Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    C.J. Robson, Radical nephrectomy for renal cell carcinoma, J. Urol. 89: 37 (1968).Google Scholar
  2. 2.
    C.J. Robson, B.M. Churchill, and W. Anderson, The results of radical nephrectomy for renal cell carcinoma, J. Urol. 101: 297 (1969).PubMedGoogle Scholar
  3. 3.
    D.G. Skinner, R.B. Colvin, C.D. Vermillion, R.C. Pfister, and W.F. Leadbetter, Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases, Cancer 28: 1165 (1971).PubMedCrossRefGoogle Scholar
  4. 4.
    J.B. deKernion and D. Berry, The diagnosis and treatment of renal cell carcinoma, Cancer 45: 1947 (1980).PubMedGoogle Scholar
  5. 5.
    G. Sufrin and G.P. Murphy, Renal adenocarcinoma, Urol. Surv. 30: 129 (1980).PubMedGoogle Scholar
  6. 6.
    M.H. Harmer, “TNM Classification of Malignant Tumors”, 3rd ed., International Union Against Cancer, Geneva (1978).Google Scholar
  7. 7.
    C.E. Cox, S.S. Lacy, W.G. Montgomery, and W.H. Boyce, Renal adenocarcinoma: 28-year review, with emphasis on rationale and feasibility of preoperative radiotherapy, J. Urol. 104: 53 (1970).PubMedGoogle Scholar
  8. 8.
    E.M. Hersh, S. Wallace, D.E. Johnson, and R.B. Bracken, Immunologic studies in human cancer, in: Cancer of the Genitourinary Tract,” D.E. Johnson and M.L. Samuels, eds., Raven Press, New York (1979), p. 47.Google Scholar
  9. 9.
    S. Wallace, V. Chuang, B. Green, D.A. Swanson, R.B. Bracken, and D.E. Johnson, Diagnostic radiology in renal carcinoma, in: Cancer of the Genitourinary Tract,” D.E. Johnson and M.L. Samuels, eds., Raven Press, New York (1979), p. 33.Google Scholar
  10. 10.
    D.A. Swanson, The current immunologic studies of renal carcinoma, Cancer Bull. 31: 36 (1979).Google Scholar
  11. 11.
    T.R. Hakala, A.E. Castro, A.Y. Elliott, and E.E. Fraley, Humoral cytotoxicity in human renal cell carcinoma, Invest. Urol. 11: 405 (1974).PubMedGoogle Scholar
  12. 12.
    K.P. Ramming and J.B. deKernion, Immune RNA therapy for renal cell carcinoma: Survival and immunologic monitoring, Ann. Surg. 186: 459 (1977).PubMedCrossRefGoogle Scholar
  13. 13.
    R.M. Bukowski, C. Jroppe, R. Reimer, J. Weich, and J.S. Hewlett, Immunotherapy (IT) of metastatic renal cell carcinoma, Proc. Amer. Soc. Clin. Oncol. 20: 402 (1979).Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • J. D. Schmidt
    • 1
  1. 1.University of California Medical CenterSan DiegoUSA

Personalised recommendations